Zev Wainberg on Combination Chemotherapy Regimens in Metastatic Pancreatic Cancer
Zev A. Wainberg, MD, discusses the implications of the findings from the phase 3 NAPOLI 3 trial for patients with metastatic pancreatic ductal adenocarcinoma.
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer
